|1.||Mahata, Sushil K: 4 articles (01/2015 - 10/2002)|
|2.||O'Connor, Daniel T: 4 articles (01/2015 - 10/2002)|
|3.||O'Dorisio, Thomas M: 3 articles (09/2014 - 07/2010)|
|4.||Howe, James R: 3 articles (09/2014 - 07/2010)|
|5.||Sánchez-Margalet, Víctor: 3 articles (11/2010 - 02/2005)|
|6.||Najib, Souad: 3 articles (11/2010 - 02/2005)|
|7.||González-Yanes, C: 3 articles (07/2001 - 06/2000)|
|8.||Sánchez-Margalet, V: 3 articles (07/2001 - 06/2000)|
|9.||Bloomston, Mark: 2 articles (03/2015 - 03/2007)|
|10.||Shah, Manisha H: 2 articles (03/2015 - 03/2007)|
11/01/1991 - "Immunohistochemical study of the distribution of pancreastatin in endocrine tumors of the pancreas and in normal pancreatic tissue: analysis of autopsy cases."
08/01/2013 - "Pancreastatin has the potential to be a diagnostic and predictive tumor marker in detecting NETs. "
07/01/2010 - "This highly specific, sensitive pancreastatin assay can detect small changes in liver tumor progression and is up to 100-fold more sensitive and specific than CgA assays in the United States."
03/01/2007 - "Although safe, it should be approached cautiously in patients with significant tumor burden as evidenced by pancreastatin levels > or =5,000 pg/ml. We do not recommend whole-liver embolization in these patients but prefer a staged approach to each lobe of the liver."
01/01/1994 - "It is likely that the predominant form of pancreastatin in human gut extracts and noninsular tumors is a 92 amino acid peptide."
|2.||Pituitary Neoplasms (Pituitary Adenoma)
10/01/2012 - "Immunohistochemistry against pancreastatin was performed in 5 patients of each of the 3 groups of pituitary adenomas. "
10/01/2012 - "Study of the involvement of pancreastatin in the physiopathology of diabetes mellitus associated with nonsecreting pituitary adenomas."
10/01/2012 - "These results argue against a role of pancreastatin in the pathogenesis of diabetes mellitus associated with nonsecreting pituitary adenomas."
10/01/2012 - "An immunostaining against pancreastatin was found in a majority of pituitary adenomas, associated or not with diabetes mellitus. "
10/01/2012 - "We evaluated the possible involvement of pancreastatin in the physiopathology of diabetes mellitus associated with nonsecreting pituitary adenomas. "
|3.||Neoplasm Metastasis (Metastasis)
03/01/2015 - "Our study suggests that patients with well-to-moderately differentiated NETs metastatic to bone have larger tumors, more frequently elevated pancreastatin, and shorter survival than patients without bone metastases, with complications of bone metastases significantly contributing to mortality and morbidity."
03/26/1991 - "Individuals with hepatic metastases and carcinoid syndrome had elevated circulating levels of pancreastatin-like immunoreactivity (mean +/- S.D. "
11/01/1989 - "High levels of pancreastatinlike immunoreactivity were detected in the plasma (2.9 pmol/ml, greater than 200-fold the normal level), pancreas (2.9 nmol/g wet wt, greater than 450-fold the normal level), and liver (1.6 nmol/g wet wt) of a patient with pancreatic insulinoma with metastasis to the liver by a sensitive and specific radioimmunoassay for human pancreastatin. "
03/26/1991 - "Chromatographic analysis of extracts of primary lung and ileal tumors, hepatic metastases from ileal tumors and plasma from individuals with carcinoid syndrome revealed molecular heterogeneity of pancreastatin-like immunoreactivity."
05/01/1993 - "Pancreastatin has different molecular forms, the major form being a high molecular form of 92 amino acids, found by the authors in human stomach- and colon extracts and in a liver metastasis of a gastrinoma. "
|4.||Hypertension (High Blood Pressure)
10/01/2002 - "The results of this study suggest that pancreastatin may contribute to the dysglycemia associated with type 2 diabetes and essential hypertension, two common human disease states in which plasma pancreastatin levels are elevated."
02/01/1995 - "These results show an increase in pancreastatin levels in hypertensive patients, suggesting that pancreastatin might play a role in the pathophysiology of essential hypertension."
02/01/1995 - "Increased plasma pancreastatin-like immunoreactivity levels in non-obese patients with essential hypertension."
05/01/1997 - "We hypothesized that pancreastatin alongside the sympathoadrenal system might have a part in the insulin resistance of these patients, and this metabolic syndrome could play a role in the pathogenesis and complications of hypertension. "
08/01/1995 - "Plasma pancreastatin-like immunoreactivity correlates with plasma norepinephrine levels in essential hypertension."
|5.||Hepatocellular Carcinoma (Hepatoma)
07/01/2001 - "We have previously characterized pancreastatin receptor and signalling in rat liver and HTC hepatoma cells. "
06/02/2000 - "Characterization of pancreastatin receptor and signaling in rat HTC hepatoma cells."
03/01/1999 - "Our aim was to study the possible cross-talk between pancreastatin and the insulin signalling system, by using the well-studied insulin sensitive rat hepatoma HTC cells. "
07/01/2001 - "Therefore, the NO and the cGMP produced by the NO-activated guanylate cyclase may mediate the dose-dependent inhibitory effect of pancreastatin on growth and proliferation in HTC hepatoma cells."
07/01/2001 - "Contrary to the expected results, we have found that pancreastatin inhibits protein and DNA synthesis in HTC hepatoma cells. "
|4.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|6.||Immune Sera (Antisera)
|8.||Serotonin (5 Hydroxytryptamine)
|9.||Messenger RNA (mRNA)
|10.||Phosphopyruvate Hydratase (Enolase)